InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,187.70
(
0.13%
)
US TECH 100
17,607.60
(
-0.03%
)
Dow Jones
38,884.26
(
0.08%
)
Brent Oil
82.27
(
-0.72%
)
Bitcoin
62,241.87
(
-0.15%
)
Post# of 345768
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

biopharm

Send PM Follow Ignore
Followers 86
Posts 12714
Boards Moderated 0
Alias Born 10/12/2010

biopharm

Re: semper post# 228376

Friday, 07/31/2015 9:52:31 PM

Friday, July 31, 2015 9:52:31 PM

Post# of 345768
thanks semper!

I like this and they will certainly be getting lots of hits on this page when trials begin and patients begin to start investigating all there is to know about "BAVITUXIMAB" : )


bavituximab

A substance being studied in the treatment of several types of cancer and infections caused by certain viruses. It binds to substances on the surface of tumor cells, certain viruses, and cells infected with a virus. The immune system detects bavituximab on the cells and the viruses and may destroy them. It is a type of monoclonal antibody and a type of targeted therapy agent. Also called Tarvacin.

https://www.mskcc.org/term/bavituximab

"Bavituximab is a first-in-class phosphatidylserine (PS)-targeting monoclonal antibody that is the cornerstone of a broad clinical
pipeline." -- Big Pharmas nightmare... unless they are fortunate enough to have The Bavi Edge!

Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote
Recent CDMO News
More CDMO News
InvestorsHub NewsWire

FEATURED Cannabix Technologies Launches New Compact Breath Logix Workplace Series and Prepares for Delivery to South Africa • May 7, 2024 8:51 AM

Moon Equity Holdings, Corp. Announces Acquisition of Wikolo, Inc. • MONI • May 7, 2024 9:48 AM

NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM

ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM

Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM

Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM

Start posting your company's news
Only $200 per official company press release!